{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:04:32Z","timestamp":1773281072001,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,25]],"date-time":"2008-10-25T00:00:00Z","timestamp":1224892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00417-008-0976-3","type":"journal-article","created":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T07:55:34Z","timestamp":1224834934000},"page":"541-548","source":"Crossref","is-referenced-by-count":32,"title":["Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization"],"prefix":"10.1007","volume":"247","author":[{"given":"Young Sang","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,25]]},"reference":[{"key":"976_CR1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","volume":"26","author":"RL Avery","year":"2006","unstructured":"Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352\u2013354, doi: 10.1097\/00006982-200603000-00016","journal-title":"Retina"},{"key":"976_CR2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363\u2013372, doi: 10.1016\/j.ophtha.2005.11.019","journal-title":"Ophthalmology"},{"key":"976_CR3","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","volume":"66","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843\u20137848, doi: 10.1158\/0008-5472.CAN-06-1010","journal-title":"Cancer Res"},{"key":"976_CR4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","volume":"79","author":"LF Barros","year":"2007","unstructured":"Barros LF, Belfort-Jr R (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389\u2013394, doi: 10.1590\/S0001-37652007000300004","journal-title":"An Acad Bras Cienc"},{"key":"976_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","volume":"142","author":"ZF Bashshur","year":"2006","unstructured":"Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1\u20139, doi: 10.1016\/j.ajo.2006.02.037","journal-title":"Am J Ophthalmol"},{"key":"976_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1096\/fasebj.11.5.9141503","volume":"11","author":"L Beck Jr","year":"1997","unstructured":"Beck L Jr, D\u2019Amore PA (1997) Vascular development: cellular and molecular regulation. FASEB J 11:365\u2013373","journal-title":"FASEB J"},{"key":"976_CR7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archopht.1990.01070060121061","volume":"108","author":"D BenEzra","year":"1990","unstructured":"BenEzra D, Hemo I, Maftzir G (1990) In vivo angiogenic activity of interleukins. Arch Ophthalmol 108:573\u2013576","journal-title":"Arch Ophthalmol"},{"key":"976_CR8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","volume":"19","author":"C Cursiefen","year":"2000","unstructured":"Cursiefen C, Rummelt C, K\u00fcchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526\u2013533, doi: 10.1097\/00003226-200007000-00025","journal-title":"Cornea"},{"key":"976_CR9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","volume":"125","author":"JJ DeStafeno","year":"2007","unstructured":"DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125:834\u2013836, doi: 10.1001\/archopht.125.6.834","journal-title":"Arch Ophthalmol"},{"key":"976_CR10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"M Erdurmus","year":"2007","unstructured":"Erdurmus M, Totan Y (2007) Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 245:1577\u20131579, doi: 10.1007\/s00417-007-0587-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"976_CR11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342, doi: 10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"976_CR12","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.21641","volume":"118","author":"HJ Kwak","year":"2006","unstructured":"Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, Lee SH, Kim MS, Lee HW, Shin WS, Park IC, Rhee CH, Hong SI (2006) Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR\/Flk-1) phosphorylation. Int J Cancer 118:2711\u20132720, doi: 10.1002\/ijc.21641","journal-title":"Int J Cancer"},{"key":"976_CR13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RP Manzano","year":"2007","unstructured":"Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Ch\u00e9vez-Barrios P (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804\u2013807, doi: 10.1136\/bjo.2006.107912","journal-title":"Br J Ophthalmol"},{"key":"976_CR14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035\u20131047, doi: 10.1016\/j.ophtha.2005.02.007","journal-title":"Ophthalmology"},{"key":"976_CR15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","volume":"91","author":"S Peters","year":"2007","unstructured":"Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU (2007) Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 91:827\u2013831, doi: 10.1136\/bjo.2006.109702","journal-title":"Br J Ophthalmol"},{"key":"976_CR16","first-page":"2514","volume":"41","author":"W Philipp","year":"2000","unstructured":"Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514\u20132522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"976_CR17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336\u2013339","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"976_CR18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278, doi: 10.1097\/00006982-200603000-00004","journal-title":"Retina"},{"key":"976_CR19","first-page":"511","volume":"137","author":"C Sunderk\u00f6tter","year":"1990","unstructured":"Sunderk\u00f6tter C, Roth J, Sorg C (1990) Immunohistochemical detection of bFGF and TNF-alpha in the course of inflammatory angiogenesis in the mouse cornea. Am J Pathol 137:511\u2013515","journal-title":"Am J Pathol"},{"key":"976_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335\u2013345, doi: 10.1007\/s10456-004-8272-2","journal-title":"Angiogenesis"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0976-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-008-0976-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0976-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:42Z","timestamp":1559072442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-008-0976-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,25]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1007\/s00417-008-0976-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,25]]}}}